Introduction: Nephrotoxicity is one of the complications the use of doxorubicin (DXR) which may be caused by the formation of free radicals. The aim of this study was to investigate the effects of pravastatin (PS) on doxorubicin-induced nephrotoxocity. Methods: The rats were divided into control, doxorubicin (15 mg/kg, i.p.), PS (20 mg/kg orally, 5 days prior to DXR injection) + DXR and DXR + PS (5 days after DXR injection) groups. At the end of the 20 th day, kidneys were removed for evaluation. Podocin mRNA and protein were determined by real-time PCR and Western blotting. Also, the level of tissue's malondialdehyde (MDA), catalase (CAT), Superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities were determined. Results: Adminstration of pravastatin increased (P < 0.005) the mRNA and protein expression of podocin and the activities of CAT, SOD and GPx which were decreased in doxorubicin group. Pravastatin also, reduced (P < 0.005) the elevated MDA level in doxorubicin group. Conclusion: The present study showed that that pravastatin can improve doxorubicin-induced nephrotoxicity in rats which is associated with the increase in expression of podocin and antioxidant enzymes activities, and decrease in level of MDA.
INTRODUCTION
Cancer is the main cause of mortality in worldwide and claims more than 6 million lives annually. Chemotherapy is not recog nized as a safe treatment method because of the side effects of the drugs on the healthy organs. Between the different types of chemo therapeutic drugs, doxorubicin (DXR), which belongs to anthracycline group of antibiotics, is commonly used. 13 DXR has its own dosedependent cytotoxicity on kidney and other organs similar to the side effects of other anticancer drugs. 4 However the DXRinduced nephrotoxicity mechanism has not exactly been known, it is supposed that the toxicity may be interceded via 21-11-2016 membrane lipid peroxidation, irondepen dent oxidative injury of biological macro molecules, free radical formation and oxidation of protein 5 while, the main patho genic mechanism seem to be the production of toxic reactive oxygen species (ROS). 6, 7 Many in vitro and in vivo researches have shown that metabolites of reactive oxygen containing superoxide anion (0 2 -), free radical species, hydroxyl radical (·OH -) and hydro gen peroxide (H 2 O 2 ) are main mediators of tissue damage. 8 It has been reported that the important causative agent of DXRinduced nephrotoxicity is the involvement of oxygen radicalinduced damage of membrane lipids. 9 According to the available evidence, DXR leads to podocyte damage. 10 This is probable by using the DXR through generating reactive oxygen. 11 Injury to podocyte leads to actin cytoskeleton disarrangement and loss of structural entirety that results in foot process effacement and podocyte loss, ultimately leading to progressive nephropathy. Thus, therapies that inhibit podocyte damage and loss will have a main clinical effect in management of glomerular disease. 12 According to previous studies, statins can directly bind and metabolize reactive oxygen species resulting in reduction of intracellular reactive oxygen species content. 13, 14 In the kidney, statins can prevent mitogen activated protein kinase and nuclear factor kappa B and also clear off free radicals. Moreover, they prevent the activation of signaling pathways through ROS. 15, 16 Overall, statins may exert benefits against renal damage in experimental conditions of acute or chronic renal function impairment. 17 Pravastatin (PS), which belongs to the statins group, has been indicated to diminish the incidence of strokes and heart attacks induced by cardiovascular disorders. 18 In recent studies, the antioxidant and anti-inflammatory properties of pravastatin were recognized. In an in vivo study, the H 2 O 2 induced endothelial dysfunction was inhibited by pravastatin. 19 This study, therefore, was focused to evaluate the effect of pravastatin on levels of filtration slit diaphragm protein and oxidative stress in doxorubicin induced nephrotoxicity
MATERIALS AND METHODS

Chemicals and Drugs
Doxorubicin and pravastatin was purchased from Sigma (Sigma Chemical Co. St. Louis, USA). Antibodies were purchased from Santa Cruz (Santa Cruz Biotechnology, USA).
Experimental animals and experimental protocol
The present study protocol was reviewed and approved by the Ethics Committee of Ahvaz University of Medical Sciences. Male Sprague Dawley rats (150-170 g), were obtained from animals house center of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. The animals were allowed unre stricted access to water and rat chow. The rats were randomly divided into four groups (6 rats each): Control group; receiving distilled water for 20 days orally, DXR group; receiving single i.p. dose of 15 mg/kg DOX, PS + DXR group; receiving pravastatin (20 mg/kg/day orally) 5 days prior to DXR injection and DXR+ PS group; receiving pravastatin (20 mg/kg/day orally) 5 days after DXR injection. Pravastatin sodium, was freshly pre pared in distilled water and given to animals. At the end of treatment on 20 th day after injection of DXR, The animals were weighed and euthanized. The kidneys were removed, weighed and stored at 80 ºC.
Real-time polymerase chain reaction
Total RNA was extracted from renal cortex tissues using an RNeasy Plus Mini Kit (Qiagen, USA) according to the manufacturer's instructions. To quantify the expression of mRNA, the realtime SYBRGreen assay was performed as previously described . 20 Primer sets were as follows: Podocin forward, 5-tggaagctgaggcacaaaga -3, Podocin reverse, 5-agaatctcagccgccatcct -3; GAPDH forward, 5-tggtctacatgttccagtatgact -3, GAPDH reverse, 5-ccatttgatgttggcgggatctc -3.
Western blotting
The renal cortex was homogenized in RIPA buffer (consisting of 0.1% sodium dodecyl sulfate [SDS], 1% sodium deoxycholate, 1% Triton X-100, 150 mM NaCl, 10 mM EDTA, and 25 mM TrisHCl (pH 7.2) and protease inhibitors using a homogenizer. Then, were centrifuged at 13,000 × g at 4 ºC for 20 minutes and the supernatants were collected. The protein concentration was determined by Bradford method. A total of 75 µg of protein of each sample was separated by 10% SDS-PAGE, electroblotted onto PVDF membrane. The membrane was blocked in 5% bovine serum albumin in TBS for 2 h, and then incubated with primary anti body (1:200 dilution) of podocin overnight at 4 °C. The membrane was washed with Tris-buffered saline with 0.02% Tween-20 and incubated with 1:5000 diluted secondary donkey antigoat IgG-HRP (Santa Cruz Biotechnology) for 1 h at room temperature . The bound secondary antibody was detected by enhanced chemilu minescence system (Najm Biotech ECL Kit, Iran).
Estimation of lipid peroxidation (Malondialdehyde)
The kidneys were homogenized in Tris-HCl buffer, pH 7.4 (10 mM, pH 7.4) at a concentration of 5% (w/v) with a homogenizer (Model silent crusherM; Heidolph Instruments, Donau, Germany). The homogenates were centrifuged at 10,000 × g at 4 °C for 20 min. Levels of malondialdehyde (MDA), a validated index of lipid peroxidation, was estimated colorimetrically by thiobar bituric acid reactive substances (TBARS) as described in previous study. 21 
Determination of antioxidant enzymes activity
Catalse (CAT). CAT activity was measured according to the method of described in our previous study. 22 The 0.1 ml of the supernatant was pipetted into cuvette containing 1.9 ml of 50 mM phosphate buffer (pH 7.0). Reaction was initiated by the addition of 1. . The decrease in absorbance was measured at 340 nm and the results were expressed as unit/ g tissue.
Statistical Analysis
All of the data were expressed as mean ± SD. The data obtained from various groups were statistically analyzed using one way ANOVA, followed by tukey -test. P < 0.05 was considered statistically significant. All statistical analyses were performed with SPSS for Windows, version 15.0 (SPSS Inc., Chicago, IL, USA). Table 1 , displays the mean of body and kidney weight in different groups. DXR treatment significantly decreased body weigh when compared to control (p < 0.01) but administration of pravastatin had no notable effect on body weight in PS + DXR and DXR + PS groups compared with DXR group. We didn't find any differ ence in kidney weight of rats in different groups (p > 0.05).
RESULTS
Effect of pravastatin on body and kidney weights
Effect of pravastatin on mRNA and protein expression of podocin
The mRNA and protein expression of podocin were significantly decreased in DXR group compared with control (P < 0.001). However, pravastatin could signifi cantly upregulate the expressions of podocin in mRNA and protein levels in both groups of PS + DXR and DXR + PS as compared with DXR group (P < 0.001) ( Figure. 1 and 2 ). 
Effect of pravastatin on renal MDA level and
The effect of pravastatin on DXR-induced elevation of lipid peroxidation (expressed as MDA) level in the kidney tissue homogenate that is shown in Figure 3 . Treatment with DXR caused significant increase in MDA content of kidney compared with control (P < 0.001). But treat ment with pravastatin in PS + DXR and DXR + PS groups markedly decreased elevated level of MDA in DXR group (P < 0.005).
Effect of pravastatin on renal antioxidant enzymes activity
The activities of renal enzymes CAT, SOD, GPx are shown in Table 2 . The renal CAT, GPx, and GPx activities were significantly lower in DXR group then control group (P < 0.001). Concomitant treatment with pravastatin and DXR in both groups significantly restored these changes in antioxidant enzymes activity when compared to DOX treated group (P < 0.005).
DISCUSSION
In the present study, our first goal was to demonstrate the intense correlation between DXRrelated lipid peroxidation, antioxidant enzymes and expression of podocin mRNA and protein in kidney damage and the protective effects of pravastatin on these parameters. The current study shows that DXR decreased body weight, but had no effect on kidney weight. We also found that pravastatin did not cause any change in body and kidney weight in the groups PS + DXR and DXR + PS when compared to DXR group. The results of current study are in accordance with earlier studies.
1,2325
Our findings demonstrated that podocin mRNA and protein were significantly dropped with DXR treatment. Podocin, as a scaffolding protein, is one of protein constituents of the filtration slit diaphragm (SD) which has a key role in maintaining the function and structure of SD. Studies of in vivo and in vitro have supported a scaffolding role of podocin in lipid rafts of foot process membrane in podocytes, that are vital for SD function and structure. 26, 27 In summary, the function and the structure of podocytes are influenced by SD proteins such as podocin. One of momentous interven tional strategies for renal damage is inhibition and cure of podocyte injury. The results this study indicated that pravastatin administration upregulated podocin mRNA and protein expression before and after injecting DXR. Many previous studies showed that statins restored the reduced expressions of podocin in renal injury which these result are consistent with our findings.
28, 29 We have found that DXR increased lipid peroxidation as well as reduced antioxidant enzymes. As mentioned, DXR has toxicity effects for different organs such as kidney. It has been reported that the generation of reactive oxygen and nitrogen species (ROS and RNS), lipid peroxidation and reduced antioxidan levels are the molecular mecha nisms responsible for toxicity effects of DXR . 30, 31 In addition, we have observed a decline in MDA levels with an increase in antioxidant enzymes (CAT, SOD The values are mean values ± SD, n = 6. * p < 0.05 compared to control. and GPx) activity in groups which received pravastatin. Statins represent antioxidant activities by many mecha nisms including increasing the redox regulatory activity of thioredoxin by decreasing in myeloperoxidase and nitric oxide derived oxidants formation, by reducing in the necessary NADPH oxidase expression, by enhancing of the activity of the serum paroxanase I and by increasing level of serum glutathione. 32, 33 However, more studies will be needed to clear the mechanism(s) of the antioxidant effects of pravastatin. Our results are in agreement with previous studie .
PS (pravastatin), DXR (doxorubicin)
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CONCLUSION
These results indicate that pravastatin reverse decreased levels of podocin mRNA and protein which induced by DXR. Also, our data provide more evidence that pravastatin may play an important role as an exogenous antioxidant, which may account, at least in part, for pharmacological action of pravastatin. 
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